RecruitingPhase 1NCT04637763
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
Studying Lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Caribou Biosciences, Inc.
- Intervention
- CB-010(genetic)
- Enrollment
- 72 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2025
Study locations (30)
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
- HonorHealth, Scottsdale, Arizona, United States
- University of Arizona Cancer Center, Tucson, Arizona, United States
- University of Arkansas, Little Rock, Arkansas, United States
- University of California San Diego Moores Cancer Center, La Jolla, California, United States
- University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, California, United States
- Chao Family Comprehensive Cancer Center/University of California Irvine, Orange, California, United States
- Advent Health, Orlando, Florida, United States
- Bone and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States
- Georgia Cancer Center at Augusta University, Augusta, Georgia, United States
- Holden Comprehensive Cancer Center at the University of Iowa, Iowa City, Iowa, United States
- University of Kentucky Markey Cancer, Lexington, Kentucky, United States
- Norton Cancer Institute, Louisville, Kentucky, United States
- Tufts Medical Center, Boston, Massachusetts, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04637763 on ClinicalTrials.govOther trials for Lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07511426U96-CAR-T-Cells For R/R B-ALLThe First Affiliated Hospital of Soochow University
- RECRUITINGPHASE2NCT07316010Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell LymphomaM.D. Anderson Cancer Center
- RECRUITINGPHASE2NCT07372352Zeprumetostat, Azacitidine Combined With Lipo-MIT in R/R PTCLThe First Affiliated Hospital of Soochow University
- RECRUITINGPHASE1, PHASE2NCT07575919Targeted CD22/CD19 CAR-T Therapy for Consolidation in Standard-Risk B-ALLLiping Dou
- ACTIVE NOT RECRUITINGPHASE1NCT07198087A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Healthy ParticipantsOno Pharmaceutical Co. Ltd
- RECRUITINGNANCT07191431A Clinical Study on the Efficacy and Safety of Methotrexate (MTX) or Thiotepa (for MTX Intolerance) or Temozolomide (TMZ) Combined With Orelabrutinib and Selinexor in Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma（SELINA）Ruijin Hospital
- RECRUITINGPHASE1NCT07140016A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)Astellas Pharma Global Development, Inc.
- RECRUITINGPHASE1, PHASE2NCT07018752A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell LymphomasThe Lymphoma Academic Research Organisation